Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0825 Kinnate
BioCentury & Getty Images

Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

RA Capital leads round to advance two programs towards IND

A crossover-heavy syndicate for Kinnate’s series C suggests an IPO could be on the horizon.

Aug 26, 2020 | 1:42 AM GMT

The presence of half a dozen crossover investors in Kinnate’s $98 million series C round suggests an IPO could be the next financing for the precision oncology company. 

If it does go public this year before its

Read the full 835 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE